Stock Analysis
Insmed Incorporated (INSM) Stock Analysis
Insmed Incorporated (INSM) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Insmed Incorporated (INSM) currently has an AIQ Score of 57/100, indicating a neutral setup. Momentum is the strongest factor at 61/100. Risk is the weakest current factor at 49/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
INSM at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $121.16 |
| AIQ Score | 57/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Strong Buy |
| Market Cap | $26.51B |
| P/E Ratio (TTM) | -42.96 |
| Forward P/E | — |
| EPS (Q3 FY2026) | -$0.46 |
| Revenue (Q3 FY2026) | $524.43M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 0.55 |
| Volume | 1.54M |
| 52-week range | $90.39-$212.75 |
| RSI 14 | 65.01 |
| 50-Day SMA | $110.82 |
| 200-Day SMA | $123.16 |
| Analyst Price Target | $191.13 |
| Next Earnings | Feb 18, 2027 |
INSMInsmed Incorporated
Healthcare / Biotechnology
Low Priority
Above Peers
Latest quote
- Momentum61
- Value55
- Quality58
- Risk resilience49
- Sentiment—
INSM Stock Analysis Summary
Insmed Incorporated (INSM) currently has an AIQ Score of 57/100, indicating a neutral setup. Momentum is the strongest factor at 61/100. Risk resilience is the weakest current factor at 49/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, INSM has AIQ Score of 57/100 with Momentum base of 61/100 and fading Risk resilience at 49/100. Wait for component alignment before adding exposure.
Healthcare · 2.62% stock move · INSM classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is INSM Bullish or Bearish Right Now?
INSM currently has a neutral overall setup. Momentum is the strongest factor at 61/100, while Risk Resilience is weakest at 49/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Price is +9.33% above its 50-day SMA.
- - Analyst target implies +57.75% upside from the latest quote.
- - Technical consensus has more buy votes than sell votes (36 vs 8).
- - Risk Resilience is weak at 49/100.
- - Price is -1.63% below its 200-day SMA.
Current Consensus
INSM's Technical Analysis Consensus is currently Strong Buy, with 36 buy, 2 neutral, and 8 sell votes. INSM's 14-day RSI is 65.01, which places the stock in a constructive momentum range. INSM's beta is 0.55, indicating lower market sensitivity than the broad market.
What Changed in INSM?
The largest recent change in INSM is AIQ Score moving up by 1.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the INSM Outlook?
The current neutral outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
INSM Decision Framework
Public evidence layers, setup checks, and risk context for Insmed Incorporated.
Insmed Incorporated (INSM) Stock Analysis
Insmed Incorporated has an AIQ Score of 57/100 in a Neutral regime. Momentum is strongest at 61/100. Beta is 0.55, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | INSM is in a Neutral AIQ regime with score 57/100. |
| Signal Conflict | The primary conflict is that momentum leads at 61/100 while risk lags at 49/100. |
| Factor Evidence | Momentum 61/100 · Value 55/100 · Quality 58/100 · Risk 49/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 61/100.
Momentum is 61/100 and RSI (14) is 65.0.
INSM is in a Neutral regime at 57/100.
Risk factor is 49/100 with beta 0.55 and annual volatility 63.12%.
Current conflict: momentum leads at 61/100 while risk lags at 49/100.
INSM Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
INSM Fundamentals
INSM valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
INSM Technical Analysis
INSM technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
INSM Stock Catalysts
Track INSM earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
INSM Dividend Analysis
INSM dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
INSM Financial Data
INSM revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
INSM Risk Analysis
INSM volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
INSM Stock News
INSM stock news, market tone, recent headlines, and catalyst context.
INSM vs Biotechnology Peers
Current peer cohort: INSM · INVA · IRON · JAZZ · KOD. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| INSM Current stock | 57/100 | 55/100 | 61/100 | 49/100 | -0.48 | 63.12% | Current |
| INVA Innoviva, Inc. | 67/100 | 92/100 | 43/100 | 74/100 | -0.64 | 25.21% | INSM vs INVA |
| IRON Disc Medicine, Inc. | 65/100 | — | 75/100 | 51/100 | 0.1 | 63.55% | INSM vs IRON |
| JAZZ Jazz Pharmaceuticals plc | 73/100 | 79/100 | 66/100 | 73/100 | 1.47 | 38.64% | INSM vs JAZZ |
| KOD Kodiak Sciences Inc. | 52/100 | — | 91/100 | 44/100 | 1.43 | 205.61% | INSM vs KOD |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for INSM: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching INSM
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for INSM
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
INSM Stock FAQ
What is INSM stock price today?
Insmed Incorporated's current stock price is $121.16. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is INSM bullish or bearish right now?
INSM's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is INSM's market cap?
INSM's market cap is $26.51B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is INSM's current P/E ratio?
INSM's current P/E ratio is -42.96 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is INSM's RSI?
INSM's 14-day RSI is 65.01 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is INSM above its 50-day and 200-day moving averages?
INSM is 9.33% from its 50-day SMA and -1.63% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is INSM's next earnings date?
INSM's next earnings date is currently listed as Feb 18, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does INSM pay a dividend?
INSM's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.